Tags

Type your tag names separated by a space and hit enter

A new treatment regimen for rosacea: onabotulinumtoxinA.
J Drugs Dermatol. 2012 Dec; 11(12):e76-9.JD

Abstract

Rosacea is a cutaneous condition with several clinical subtypes that are commonly seen in daily medical practice. There are many different treatment modalities for each of the physical findings associated with this disease, and all have varying results. As the use of onabotulinumtoxinA rises, its benefit in the treatment of a growing number of medical diseases increases. The authors report anecdotal evidence of patients with rosacea experiencing improved symptoms of erythema and flushing after treatment with intradermal, microdroplets of onabotulinumtoxinA. There were no adverse events reported for any of the treatments. The mechanism of action through a likely neurogenic component to vascular dysfunction, inflammation, and hypersebaceous activity is reviewed.

Links

Publisher Full Text

Authors+Show Affiliations

Dayan SH
Department of Otolaryngology, University of Illinois, Chicago, IL, USA. sdayan@drdayan.com
Pritzker RN
No affiliation info available
Arkins JP
No affiliation info available

MeSH

Botulinum Toxins, Type AErythemaFemaleFlushingHumansInjections, IntradermalMicroinjectionsMiddle AgedRosaceaSebaceous GlandsSkinSweatingTelangiectasisTreatment Outcome

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

23377526

Citation

Dayan, Steven H., et al. "A New Treatment Regimen for Rosacea: OnabotulinumtoxinA." Journal of Drugs in Dermatology : JDD, vol. 11, no. 12, 2012, pp. e76-9.
Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol. 2012;11(12):e76-9.
Dayan, S. H., Pritzker, R. N., & Arkins, J. P. (2012). A new treatment regimen for rosacea: onabotulinumtoxinA. Journal of Drugs in Dermatology : JDD, 11(12), e76-9.
Dayan SH, Pritzker RN, Arkins JP. A New Treatment Regimen for Rosacea: OnabotulinumtoxinA. J Drugs Dermatol. 2012;11(12):e76-9. PubMed PMID: 23377526.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A new treatment regimen for rosacea: onabotulinumtoxinA. AU - Dayan,Steven H, AU - Pritzker,Rachel N, AU - Arkins,John P, PY - 2013/2/5/entrez PY - 2013/2/5/pubmed PY - 2013/8/14/medline SP - e76 EP - 9 JF - Journal of drugs in dermatology : JDD JO - J Drugs Dermatol VL - 11 IS - 12 N2 - Rosacea is a cutaneous condition with several clinical subtypes that are commonly seen in daily medical practice. There are many different treatment modalities for each of the physical findings associated with this disease, and all have varying results. As the use of onabotulinumtoxinA rises, its benefit in the treatment of a growing number of medical diseases increases. The authors report anecdotal evidence of patients with rosacea experiencing improved symptoms of erythema and flushing after treatment with intradermal, microdroplets of onabotulinumtoxinA. There were no adverse events reported for any of the treatments. The mechanism of action through a likely neurogenic component to vascular dysfunction, inflammation, and hypersebaceous activity is reviewed. SN - 1545-9616 UR - https://www.unboundmedicine.com/medline/citation/23377526/A_new_treatment_regimen_for_rosacea:_onabotulinumtoxinA_ L2 - http://jddonline.com/articles/dermatology/S1545961612E0076X DB - PRIME DP - Unbound Medicine ER -